JP2023531920A5 - - Google Patents
Info
- Publication number
- JP2023531920A5 JP2023531920A5 JP2022578618A JP2022578618A JP2023531920A5 JP 2023531920 A5 JP2023531920 A5 JP 2023531920A5 JP 2022578618 A JP2022578618 A JP 2022578618A JP 2022578618 A JP2022578618 A JP 2022578618A JP 2023531920 A5 JP2023531920 A5 JP 2023531920A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- protein according
- chain sequence
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025028465A JP2025091418A (ja) | 2020-06-23 | 2025-02-26 | 抗ｐｄ－１抗体および融合タンパク質 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043114P | 2020-06-23 | 2020-06-23 | |
| US63/043,114 | 2020-06-23 | ||
| US202063111459P | 2020-11-09 | 2020-11-09 | |
| US63/111,459 | 2020-11-09 | ||
| PCT/US2021/038740 WO2021262880A2 (en) | 2020-06-23 | 2021-06-23 | Anti-pd-1 antibodies and fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025028465A Division JP2025091418A (ja) | 2020-06-23 | 2025-02-26 | 抗ｐｄ－１抗体および融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531920A JP2023531920A (ja) | 2023-07-26 |
| JP2023531920A5 true JP2023531920A5 (enExample) | 2024-12-24 |
| JP7644151B2 JP7644151B2 (ja) | 2025-03-11 |
Family
ID=79282816
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022578618A Active JP7644151B2 (ja) | 2020-06-23 | 2021-06-23 | 抗ｐｄ－１抗体および融合タンパク質 |
| JP2025028465A Pending JP2025091418A (ja) | 2020-06-23 | 2025-02-26 | 抗ｐｄ－１抗体および融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025028465A Pending JP2025091418A (ja) | 2020-06-23 | 2025-02-26 | 抗ｐｄ－１抗体および融合タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20230416363A1 (enExample) |
| EP (3) | EP4729531A3 (enExample) |
| JP (2) | JP7644151B2 (enExample) |
| KR (1) | KR20230027267A (enExample) |
| CN (1) | CN116194471A (enExample) |
| AU (1) | AU2021296437A1 (enExample) |
| BR (1) | BR112022025632A2 (enExample) |
| CA (1) | CA3184746A1 (enExample) |
| CO (1) | CO2022018053A2 (enExample) |
| IL (1) | IL299238A (enExample) |
| MX (1) | MX2022016588A (enExample) |
| PH (1) | PH12022500029A1 (enExample) |
| WO (1) | WO2021262880A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116194471A (zh) | 2020-06-23 | 2023-05-30 | 卡德门企业有限公司 | 抗pd-1抗体和融合蛋白 |
| CN116333155A (zh) * | 2023-03-09 | 2023-06-27 | 杭州美赛生物医药科技有限公司 | 靶向pd-1和vegf的双功能抑制剂 |
| WO2025048616A1 (ko) * | 2023-08-31 | 2025-03-06 | 주식회사 지아이셀 | Il-2 단백질 및 il-15 단백질의 키메라 단백질 또는 변이체, 이를 포함하는 융합단백질, 및 이를 발현하는 유전자 조작된 세포 |
| WO2025217310A1 (en) * | 2024-04-10 | 2025-10-16 | Prolynx Llc | Pegylated il- 15 receptor alpha cytokines |
| WO2026158432A1 (zh) * | 2025-01-24 | 2026-07-30 | 江苏奥赛康生物医药有限公司 | 抗pd-1抗体-il-15前药的融合分子与化学治疗药物的组合及其应用 |
| WO2026161860A1 (en) * | 2025-01-27 | 2026-07-30 | Kadmon Corporation, Llc | Dosing of immunocytokines for cancer treatment |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| ATE329263T1 (de) * | 1998-10-30 | 2006-06-15 | Jonathan L Miller | Regionen variabler schwerer ketten und variabler leichter ketten von antikörpern für humanes blutplättchen-glykoprotein ib alpha |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| GB0816461D0 (en) * | 2008-09-09 | 2008-10-15 | Univ Manchester | Biomass |
| WO2011130417A2 (en) * | 2010-04-15 | 2011-10-20 | Amgen Inc. | HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS |
| JP6251570B2 (ja) * | 2010-09-21 | 2017-12-20 | アルター・バイオサイエンス・コーポレーション | 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法 |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| LT2748201T (lt) * | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
| HK1200850A1 (en) * | 2011-09-23 | 2015-08-14 | 罗氏格黎卡特股份公司 | Bispecific anti-egfr/anti igf-1r antibodies |
| WO2014023709A1 (en) * | 2012-08-09 | 2014-02-13 | Roche Glycart Ag | Asgpr antibodies and uses thereof |
| EP3027649B1 (en) * | 2013-08-01 | 2020-04-01 | F.Hoffmann-La Roche Ag | Tnfa-il-17 bispecific antibodies |
| US8945560B1 (en) * | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| LT3094351T (lt) * | 2014-01-15 | 2022-04-11 | Kadmon Corporation, Llc | Imunitetą moduliuojantys agentai |
| JP6996979B2 (ja) * | 2015-03-31 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 三量体ｔｎｆファミリーリガンドを含む抗原結合分子 |
| AU2016326575A1 (en) * | 2015-09-25 | 2018-04-12 | Altor Bioscience Corporation | Interleukin-15 superagonist significantly enhances graft-versus-tumor activity |
| EP3455254B1 (en) * | 2016-05-11 | 2021-07-07 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety |
| KR102048476B1 (ko) * | 2016-08-05 | 2019-11-26 | 주식회사 와이바이오로직스 | 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도 |
| MX2019004327A (es) | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
| LT3535298T (lt) * | 2016-11-02 | 2021-12-27 | Jounce Therapeutics, Inc. | Antikūnai prieš pd-1 ir jų panaudojimas |
| AU2018291497A1 (en) * | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| GB201803745D0 (en) * | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| CA3097593A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| CA3116188A1 (en) | 2018-10-12 | 2020-04-16 | Xencor, Inc. | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof |
| CN116194471A (zh) | 2020-06-23 | 2023-05-30 | 卡德门企业有限公司 | 抗pd-1抗体和融合蛋白 |
-
2021
- 2021-06-23 CN CN202180050584.1A patent/CN116194471A/zh active Pending
- 2021-06-23 PH PH1/2022/500029A patent/PH12022500029A1/en unknown
- 2021-06-23 AU AU2021296437A patent/AU2021296437A1/en active Pending
- 2021-06-23 BR BR112022025632A patent/BR112022025632A2/pt unknown
- 2021-06-23 KR KR1020237002551A patent/KR20230027267A/ko active Pending
- 2021-06-23 WO PCT/US2021/038740 patent/WO2021262880A2/en not_active Ceased
- 2021-06-23 US US18/011,878 patent/US20230416363A1/en not_active Abandoned
- 2021-06-23 EP EP26162958.8A patent/EP4729531A3/en active Pending
- 2021-06-23 CA CA3184746A patent/CA3184746A1/en active Pending
- 2021-06-23 IL IL299238A patent/IL299238A/en unknown
- 2021-06-23 EP EP21828684.7A patent/EP4168124A4/en active Pending
- 2021-06-23 EP EP25184626.7A patent/EP4610275A3/en active Pending
- 2021-06-23 JP JP2022578618A patent/JP7644151B2/ja active Active
- 2021-06-23 MX MX2022016588A patent/MX2022016588A/es unknown
-
2022
- 2022-12-13 CO CONC2022/0018053A patent/CO2022018053A2/es unknown
-
2024
- 2024-12-20 US US18/989,801 patent/US12612460B2/en active Active
-
2025
- 2025-02-26 JP JP2025028465A patent/JP2025091418A/ja active Pending
-
2026
- 2026-01-02 US US19/438,935 patent/US20260176362A1/en active Pending
- 2026-04-14 US US19/647,316 patent/US20260217831A1/en active Pending